Ï㽶ÊÓƵ

Michael A. Zimmerman
( out of 44 reviews )

Michael A. Zimmerman, MD, FACS

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Salt Lake City
801-587-8808

Primary Children's Hospital

Salt Lake City
801-662-5566

Transplant Center

Transplant Center
Salt Lake City
801-581-2121

Ï㽶ÊÓƵ of Utah Hospital

Liver Transplant
Salt Lake City
801-581-2121

  • Michael A. Zimmerman, MD, is a transplant and hepatobiliary surgeon specializing in liver, kidney, and pancreas transplantation. His interests include clinical outcomes in solid organ abdominal transplant, and mitigating preservation and reperfusion injury in translational research.

    Dr. Zimmerman received his MD from the Ï㽶ÊÓƵ of California at San Francisco and completed his residency at the Ï㽶ÊÓƵ of Colorado. He completed fellowship training in Transplant and Hepatobiliary Surgery at the Ï㽶ÊÓƵ of California Los Angeles. He has published over 100 peer-reviewed publications.

    Dr. Zimmerman's research focuses on the role of purinergic signaling and mitochondrial injury in liver ischemia-reperfusion injury.

    He currently serves as a professor of surgery in the Department of Surgery, Division of Transplant & Advanced Hepatobiliary Surgery at Ï㽶ÊÓƵ of Utah Health. He is also the Director of the Adult kidney and pancreas transplant program, the director of the pediatric kidney transplant program at Primary Children's Hospital, and the Director of Transplant Research.

    Dr. Zimmerman's goal is to expand the donor pool using various organ resuscitation methods to increase the number of transplants available.

    In his spare time, Dr. Zimmerman enjoys Utah's mountains and skiing.

    Specialties

    Board Certification

    American Board of Surgery

    Patient Rating

    4.7 /5
    ( out of 44 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 12, 2024
    UH HOSPITALS AND CLINICS

    We did not have any questions for Dr. Zimmerman since we know that the transplant surgery could potentially be years away, but he was very positive about [NAME REMOVED] and how he feels that [NAME REMOVED] will do during and following the surgery.

    June 05, 2024
    UH HOSPITALS AND CLINICS

    Very kind, professional, takes time to listen

    May 22, 2024
    UH HOSPITALS AND CLINICS

    Great doctor explains stuff really good

    May 01, 2024
    UH HOSPITALS AND CLINICS

    Dr. Zimmerman explained the surgery in a way that I could understand. He made me feel comfortable and confident going in to surgery.

    March 13, 2024
    UH HOSPITALS AND CLINICS

    Meeting Dr. Zimmerman was a delight. I would have loved him as my surgeon.

    October 09, 2023
    UH HOSPITALS AND CLINICS

    Dr. Zimmerman is a wonderful doctor and excellent surgeon. He has always taken time to answer my questions and put at ease any concerns I had, both before and following my surgery. He sincerely cares about his patients, and I know I can trust him completely to do his best. I highly recommend him!

    October 06, 2023
    UH HOSPITALS AND CLINICS

    The office visit with Dr. Zimmerman was extremely brief but he communicated pretty much all I needed to know.

    August 14, 2023
    UH HOSPITALS AND CLINICS

    I am so grateful that Dr. Zimmerman is on my care team. He exudes confidence and helps me to understand my situation and feel better about my status. He did an amazing job on my surgery and I'm glad that he's also involved in the follow up care.

    April 23, 2023
    UH HOSPITALS AND CLINICS

    Great, caring surgeon. Explains everything so patient understands. Never seems rushed and willing to listen to concerns.

    See More Patient Comments

  • Michael A. Zimmerman, MD, is a transplant and hepatobiliary surgeon specializing in liver, kidney, and pancreas transplantation. His interests include clinical outcomes in solid organ abdominal transplant, and mitigating preservation and reperfusion injury in translational research.

    Dr. Zimmerman received his MD from the Ï㽶ÊÓƵ of California at San Francisco and completed his residency at the Ï㽶ÊÓƵ of Colorado. He completed fellowship training in Transplant and Hepatobiliary Surgery at the Ï㽶ÊÓƵ of California Los Angeles. He has published over 100 peer-reviewed publications.

    Dr. Zimmerman's research focuses on the role of purinergic signaling and mitochondrial injury in liver ischemia-reperfusion injury.

    He currently serves as a professor of surgery in the Department of Surgery, Division of Transplant & Advanced Hepatobiliary Surgery at Ï㽶ÊÓƵ of Utah Health. He is also the Director of the Adult kidney and pancreas transplant program, the director of the pediatric kidney transplant program at Primary Children's Hospital, and the Director of Transplant Research.

    Dr. Zimmerman's goal is to expand the donor pool using various organ resuscitation methods to increase the number of transplants available.

    In his spare time, Dr. Zimmerman enjoys Utah's mountains and skiing.

    Board Certification and Academic Information

    Academic Departments Surgery -Primary
    Academic Divisions Transplant & Advanced Hepatobiliary Surgery
    Board Certification
    American Board of Surgery

    Education history

    Fellowship Multi-organ Transplant - Ï㽶ÊÓƵ of California, Los Angeles Fellow
    Residency General Surgery - Ï㽶ÊÓƵ of Colorado School of Medicine Resident
    Internship General Surgery - Ï㽶ÊÓƵ of Colorado School of Medicine Intern
    Professional Medical Medicine - Ï㽶ÊÓƵ of California, San Francisco School of Medicine M.D.
    Research Fellow Hematology/Oncology - Ï㽶ÊÓƵ of California, San Francisco School of Medicine Research Fellow
    Undergraduate Functional Biology - California State Ï㽶ÊÓƵ, Fresno B.A.

    Selected Publications

    Journal Article

    1. Kim J, Zimmerman MA, Shin WY, Boettcher BT, Lee JS, Park JI, Ali M, Yang M, Mishra J, Hagen CE, McGraw JE, Mathison A, Woehlck HJ, Lomberk G, Camara AKS, Urrutia RA, Stowe DF, Hong JC (2021). Effects of Subnormothermic Regulated Hepatic Reperfusion on Mitochondrial and Transcriptomic Profiles in a Porcine Model. Ann Surg. ()
    2. Nair A, Coromina Hernandez L, Shah S, Zervos X, Zimmerman M, Sasaki K, Diago T, Hashimoto K, Fujiki M, Aucejo F, Bollinger J, Kaiser TL, Miller CM, Quintini C, Fung JJ, Eghtesad B (2021). Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial. Transplantation. ()
    3. Kardashian A, Florman SS, Haydel B, Ruiz RM, Klintmalm GB, Lee DD, Taner CB, Aucejo F, Tevar AD, Humar A, Verna EC, Halazun KJ, Chapman WC, Vachharajani N, Hoteit M, Levine MH, Nguyen MH, Melcher ML, Langnas AN, Carney CA, Mobley C, Ghobrial M, Amundsen B, Markmann JF, Sudan DL, Jones CM, Berumen J, Hemming AW, Hong JC, Kim J, Zimmerman MA, Nydam TL, Rana A, Kueht ML, Fishbein TM, Markovic D, Busuttil RW, Agopian VG (2019). Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. Hepatology, 72(6), 2014-2028. ()
    4. Wong M, Narra R, Selim M, Zimmerman MA, Kim J, Padmanabhan A, Hong JC (2020). Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation. J Surg Res, 255, 99-105. ()
    5. Roth AE, Marino IR, Ekwenna O, Dunn TB, Paloyo SR, Tan M, Correa-Rotter R, Kuhr CS, Marsh CL, Ortiz J, Testa G, Sindhwani P, Segev DL, Rogers J, Punch JD, Forbes RC, Zimmerman MA, Ellis MJ, Rege A, Basagoitia L, Krawiec KD, Rees MA (2020). Global kidney exchange should expand wisely. Transpl Int, 33(9), 985-988. ()
    6. Kim J, Hagen CE, Kumar SN, Park JI, Zimmerman MA, Hong JC (2020). Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats. Transplant Direct, 6(8), e584. ()
    7. DiNorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial M, Nydam TL, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Markovic D, Busuttil RW, Agopian VG (2019). Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Ann Surg, 271(4), 616-624. ()
    8. Wong M, Kim J, George B, Eriksen C, Pearson T, Robbins J, Zimmerman MA, Hong JC (2019). Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. J Surg Res, 242, 23-30. ()
    9. Pearson T, Zimmerman MA, Kim J, Palines PA, Eriksen CM, Wong M, Selim MA, Markovic D, Hong JC (2019). Staged Biliary Reconstruction After Orthotopic Liver Transplantation: A Practical Surgical Strategy for High-Acuity Adult Recipients. Transplant Direct, 5(9), e482. ()
    10. Kim J, Martin A, Yee J, Fojut L, Geurts AM, Oshima K, Zimmerman MA, Hong JC (2018). Effects of Hepatic Ischemia-Reperfusion Injuries and NRF2 on Transcriptional Activities of Bile Transporters in Rats. J Surg Res, 235, 73-82. ()
    11. Kim J, Zimmerman MA, Lerret SM, Scott JP, Voulgarelis S, Fons RA, Vitola BE, Telega GW, Hoffman GM, Berens RJ, Hong JC (2018). Staged biliary reconstruction after liver transplantation: A novel surgical strategy for high acuity pediatric transplant recipients. Surgery, 165(2), 323-328. ()
    12. Zimmerman MA, Schiller J, Selim M, Kim J, Hong JC (2019). Management of renal failure in the liver transplant patient. Curr Transplant Rep.
    13. Zimmerman MA, Selim M, Kim J, Saeian K, Cinquegrani MP, Connolly L, Woehlck HJ, Lauer KK, Hong JC (2018). Impact of a Transplantation Critical Care Model on Short-Term Outcomes Following Liver Transplantation in High Acuity Patients: A Single-Center Experience. Transplant Proc, 50(10), 3544-3548. ()
    14. Zimmerman MA, Selim M, Kim J, Kozeniecki M, Hong JC (2018). A Specialized Transplantation Critical Care Model: Expanding Liver Transplantation Access to High-Acuity Patients. Transplant Proc, 50(9), 2619-2621. ()
    15. Baker TB, Zimmerman MA, Goodrich NP, Samstein B, Pomfret EA, Pomposelli JJ, Gillespie BW, Berg CL, Emond JC, Merion RM (2017). Biliary reconstructive techniques and associated anatomic variants in adult living donor liver transplantations: The adult-to-adult living donor liver transplantation cohort study experience. Liver Transpl, 23(12), 1519-1530. ()
    16. la Cour MF, Mehrvar S, Kim J, Martin A, Zimmerman MA, Hong JC, Ranji M (2017). Optical imaging for the assessment of hepatocyte metabolic state in ischemia and reperfusion injuries. Biomed Opt Express, 8(10), 4419-4426. ()
    17. Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, Haydel B, Hoteit M, Levine MH, Lee DD, Taner CB, Verna EC, Halazun KJ, Abdelmessih R, Tevar AD, Humar A, Aucejo F, Chapman WC, Vachharajani N, Nguyen MH, Melcher ML, Nydam TL, Mobley C, Ghobrial RM, Amundsen B, Markmann JF, Langnas AN, Carney CA, Berumen J, Hemming AW, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Busuttil RW (2017). Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg, 266(3), 525-535. ()
    18. Kim J, Kim T, Hong KS, Moon H, Oh IK, Lee SM, Hohenwalter MD, Zimmerman MA, Cronin DC, Hong JC (2016). Pre-Hepatectomy Assessment of Bile Transporter Expression by Gadoxetic Acid-Enhanced MRI in a Rat Model of Liver Cirrhosis. J Invest Surg, 30(4), 265-271. ()
    19. Zimmerman MA, Selim M, Kim J, Regner K, Saeian K, Zanowski S, Martin A, Connolly LA, Lauer KK, Woehlck HJ, Hong JC (2016). Outcome analysis of continuous intraoperative renal replacement therapy in the highest acuity liver transplant recipients: A single-center experience. Surgery, 161(5), 1279-1286. ()
    20. Hong JC, Kim J, Browning M, Wagner A, Lerret S, Segura AD, Zimmerman MA (2017). Modified associating liver partition and portal vein ligation for staged hepatectomy for hepatoblastoma in a small infant: How far can we push the envelope? Ann Surg, 266, e16-17.
    21. Chirichella TJ, Dunham CM, Zimmerman MA, Phelan EM, Mandell MS, Conzen KD, Kelley SE, Nydam TL, Bak TE, Kam I, Wachs ME (2015). Donor preoperative oxygen delivery and post-extubation hypoxia impact donation after circulatory death hypoxic cholangiopathy. World J Gastroenterol, 22(12), 3392-403. ()
    22. Samstein B, Smith AR, Freise CE, Zimmerman MA, Baker T, Olthoff KM, Fisher RA, Merion RM (2015). Complications and Their Resolution in Recipients of Deceased and Living Donor Liver Transplants: Findings From the A2ALL Cohort Study. Am J Transplant, 16(2), 594-602. ()
    23. Tak E, Ridyard D, Kim JH, Zimmerman M, Werner T, Wang XX, Shabeka U, Seo SW, Christians U, Klawitter J, Moldovan R, Garcia G, Levi M, Haase V, Ravid K, Eltzschig HK, Grenz A (2013). CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy. J Am Soc Nephrol, 25(3), 547-63. ()
    24. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS Jr, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond JC, Stiles JB, Lukose T, Chang MS, Klintmalm G (2013). Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clin Transplant, 27(6), 829-37. ()
    25. Kelly MA, Kaplan M, Nydam T, Wachs M, Bak T, Kam I, Zimmerman MA (2013). Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. Transplant Proc, 45(9), 3325-8. ()
    26. Tak E, Ridyard D, Badulak A, Giebler A, Shabeka U, Werner T, Clambey E, Moldovan R, Zimmerman MA, Eltzschig HK, Grenz A (2013). Protective role for netrin-1 during diabetic nephropathy. J Mol Med (Berl), 91(9), 1071-80. ()
    27. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm G (2012). Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl, 19(9), 1020-9. ()
    28. Zimmerman MA, Baker T, Goodrich NP, Freise C, Hong JC, Kumer S, Abt P, Cotterell AH, Samstein B, Everhart JE, Merion RM (2012). Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: a report from the adult-to-adult living donor liver transplantation cohort study consortium. Liver Transpl, 19(3), 259-67. ()
    29. Campsen J, Ray C, Zimmerman MA, Mandell MS, Kaplan M, Kam I (2012). Diagnosis and correction of hepatic vena caval obstruction following liver transplantation. Indian Journal of Transplantation, 6, 1-4.
    30. Zimmerman MA, Haskins K, Bradley B, Gilman J, Gamboni-Robertson F, Flores SC (2011). Autoimmune-mediated vascular injury occurs prior to sustained hyperglycemia in a murine model of type I diabetes mellitus. J Surg Res, 168(2), e195-202. ()
    31. Campsen J, Zimmerman MA, Narkewicz MR, Sokol RJ, Mandell MS, Kam I, Dovel D, Karrer FM (2011). Choledochoduodenostomy in pediatric liver transplantation. Pediatr Transplant, 15(3), 237-9. ()
    32. Benson AB, Burton JR Jr, Austin GL, Biggins SW, Zimmerman MA, Kam I, Mandell S, Silliman CC, Rosen H, Moss M (2011). Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl, 17(2), 149-58. ()
    33. Jani A, Zimmerman M, Martin J, Lu L, Turkmen K, Ravichandran K, Pacic A, Ljubanovi D, Edelstein CL (2011). Perfusion storage reduces apoptosis in a porcine kidney model of donation after cardiac death. Transplantation, 91(2), 169-75. ()
    34. Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I (2011). A Decade of Experience Using mTor Inhibitors in Liver Transplantation. J Transplant, 2011, 913094. ()
    35. Zimmerman MA, Kelly MA, Campsen J, Mandell MS, Wachs M, Bak T, Skibba A, Lancaster B, Kam I (2009). The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation. Clin Transplant, 24(4), E103-8. ()
    36. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, Randall JA, McMahan R, Zimmerman MA, Rangachari M, Dobrinskikh E, Busson P, Polyak SJ, Hirashima M, Rosen HR (2010). A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One, 5(3), e9504. ()
    37. Halgrimson WR, Campsen J, Mandell MS, Kelly MA, Kam I, Zimmerman MA (2010). Donor complications following laparoscopic compared to hand-assisted living donor nephrectomy: an analysis of the literature. J Transplant, 2010, 825689. ()
    38. Campsen J, Zimmerman MA, Mandell MS, Wachs M, Bak T, Forman L, Steinberg T, Kam I (2009). Hepaticoduodenostomy is an alternative to Roux-en-Y hepaticojejunostomy for biliary reconstruction in live donor liver transplantation. Transplantation, 87(12), 1842-5. ()
    39. Mandell MS, Campsen J, Zimmerman M, Biancofiore G, Tsou MY (2009). The clinical value of early extubation. Curr Opin Organ Transplant, 14(3), 297-302. ()
    40. Campsen J, Zimmerman M, Trotter J, Wachs M, Bak T, Steinberg T, Kaplan M, Kam I (2008). Liver transplantation for primary biliary cirrhosis: results of aggressive corticosteroid withdrawal. Transplant Proc, 41(5), 1707-12. ()
    41. Bennet W, Zimmerman MA, Campsen J, Mandell MS, Bak T, Wachs M, Kam I (2009). Choledochoduodenostomy is a safe alternative to Roux-en-Y choledochojejunostomy for biliary reconstruction in liver transplantation. World J Surg, 33(5), 1022-5. ()
    42. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kaplan M, Wright F, Kam I (2008). Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl, 14(9), 1281-6. ()
    43. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I (2008). Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl, 14(5), 633-8. ()
    44. Campsen J, Hendrickson RJ, Zimmerman MA, Wachs M, Bak T, Russ P, Bennet W, Trotter J, Kam I (2008). Adult right lobe live donor liver transplantation without reconstruction of the middle hepatic vein: a single-center study of 109 cases. Transplantation, 85(5), 775-7. ()
    45. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kam I (2008). Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl, 14(2), 181-5. ()
    46. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW (2006). Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc, 39(10), 3276-80. ()
    47. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, Steinberg T, Bennett W, Kam I (2007). Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int, 20(9), 747-53. ()
    48. Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, Yersiz H, Zimmerman MA, Durazo F, Han SH, Saab S, Gornbein J, Busuttil RW (2006). Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg, 244(4), 563-71. ()
    49. Cameron AM, Ghobrial RM, Yersiz H, Farmer DG, Lipshutz GS, Gordon SA, Zimmerman M, Hong J, Collins TE, Gornbein J, Amersi F, Weaver M, Cao C, Chen T, Hiatt JR, Busuttil RW (2006). Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg, 243(6), 748-53; discussion 753-5. ()
    50. Zimmerman M, Busuttil RW (2005). Long-term efficacy of percutaneous thermal ablation for patients with recurrent hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol, 3(5), 250-1. ()
    51. Yersiz H, Cameron AM, Carmody I, Zimmerman MA, Kelly BS Jr, Ghobrial RM, Farmer DG, Busuttil RW (2006). Split liver transplantation. Transplant Proc, 38(2), 602-3. ()
    52. Zimmerman MA, Busuttil RW (2006). What is the long-term efficacy of thermal ablation for patients with recurrent hepatocellular carcinoma after hepatectomy? Nat Clin Pract Gastroenterol Hepatol, 3, 251-2.
    53. Zimmerman MA, Reznikov LL, Raeburn CD, Selzman CH (2004). Interleukin-10 attenuates the response to vascular injury. J Surg Res, 121(2), 206-13. ()
    54. Selzman CH, Netea MG, Zimmerman MA, Weinberg A, Reznikov LL, Grover FL, Dinarello CA (2003). Atherogenic effects of Chlamydia pneumoniae: refuting the innocent bystander hypothesis. J Thorac Cardiovasc Surg, 126(3), 688-93. ()
    55. Zimmerman MA, Reznikov LL, Sorensen AC, Selzman CH (2003). Relative contribution of the TNF-alpha receptors to murine intimal hyperplasia. Am J Physiol Regul Integr Comp Physiol, 284(5), R1213-8. ()
    56. Selzman CH, Miller SA, Zimmerman MA, Gamboni-Robertson F, Harken AH, Banerjee A (2002). Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. Am J Physiol Heart Circ Physiol, 283(4), H1455-61. ()
    57. Raeburn CD, Calkins CM, Zimmerman MA, Song Y, Ao L, Banerjee A, Harken AH, Meng X (2002). ICAM-1 and VCAM-1 mediate endotoxemic myocardial dysfunction independent of neutrophil accumulation. Am J Physiol Regul Integr Comp Physiol, 283(2), R477-86. ()
    58. Zimmerman MA, Selzman CH, Reznikov LL, Miller SA, Raeburn CD, Emmick J, Meng X, Harken AH (2002). Lack of TNF-alpha attenuates intimal hyperplasia after mouse carotid artery injury. Am J Physiol Regul Integr Comp Physiol, 283(2), R505-12. ()
    59. Raeburn CD, Dinarello CA, Zimmerman MA, Calkins CM, Pomerantz BJ, McIntyre RC Jr, Harken AH, Meng X (2002). Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol, 283(2), H650-7. ()
    60. Zimmerman MA, Selzman CH, Reznikov LL, Raeburn CD, Barsness K, McIntyre RC Jr, Hamiel CR, Harken AH (2002). Interleukin-11 attenuates human vascular smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol, 283(1), H175-80. ()
    61. Raeburn CD, Calkins CM, Zimmerman MA, Song Y, Ao L, Banerjee A, Meng X, Harken AH (2001). Vascular cell adhesion molecule--1 expression is obligatory for endotoxin-induced myocardial neutrophil accumulation and contractile dysfunction. Surgery, 130(2), 319-25. ()
    62. Melnyk O, Zimmerman M, Kim KJ, Shuman M (1999). Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol, 161(3), 960-3. ()

    Review

    1. Kim J, Zimmerman MA, Hong JC (2020). Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. [Review]. J Gastrointest Oncol, 11(3), 601-608. ()
    2. Kim J, Zimmerman MA, Hong JC (2018). Emerging Innovations in Liver Preservation and Resuscitation. [Review]. Transplant Proc, 50(8), 2308-2316. ()
    3. Zimmerman MA, Martin A, Yee J, Schiller J, Hong JC (2017). Natural Killer T Cells in Liver Ischemia-Reperfusion Injury. [Review]. J Clin Med, 6(4). ()
    4. Zimmerman MA, Martin A, Hong JC (2016). Basic considerations in organ perfusion physiology. [Review]. Curr Opin Organ Transplant, 21(3), 288-93. ()
    5. Zimmerman MA, Schiller J, Kim J, Martin A, Selim M, Nydam TL, Cronin D 2nd, Hong JC (2015). Pathologic sequelae of allosensitization in liver transplantation. [Review]. J Surg Res, 200(1), 195-9. ()
    6. Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Thomas Purcell W, Biggins SW (2015). Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. [Review]. Liver Transpl, 21(12), 1543-52. ()
    7. Kim J, Zimmerman MA (2015). Technical aspects for live-donor organ procurement for liver, kidney, pancreas, and intestine. [Review]. Curr Opin Organ Transplant, 20(2), 133-9. ()
    8. Zimmerman MA, Kam I, Eltzschig H, Grenz A (2013). Biological implications of extracellular adenosine in hepatic ischemia and reperfusion injury. [Review]. Am J Transplant, 13(10), 2524-9. ()
    9. Zimmerman MA, Flores SC (2008). Autoimmune-mediated oxidative stress and endothelial dysfunction: implications of accelerated vascular injury in type I diabetes. [Review]. J Surg Res, 155(1), 173-8. ()
    10. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW (2008). Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. [Review]. Arch Surg, 143(2), 182-8; discussion 188. ()
    11. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Mandell S, Kam I (2007). Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. [Review]. Expert Opin Pharmacother, 8(9), 1275-82. ()
    12. Foster R, Zimmerman M, Trotter JF (2007). Expanding donor options: marginal, living, and split donors. [Review]. Clin Liver Dis, 11(2), 417-29. ()
    13. Zimmerman MA, Cameron AM, Ghobrial RM (2006). Budd-Chiari syndrome. [Review]. Clin Liver Dis, 10(2), 259-73, viii. ()
    14. Zimmerman MA, Ghobrial RM (2005). When shouldn't we retransplant? [Review]. Liver Transpl, (11 Suppl 2), S14-20. ()
    15. Raeburn CD, Zimmerman MA, Banerjee A, Cleveland CJ Jr, Harken AH (2004). Surgical applications of organ preconditioning. [Review]. Minerva Chir, 59(3), 209-18. ()
    16. Zimmerman MA, Trotter JF (2003). Living donor liver transplantation in patients with hepatitis C. [Review]. Liver Transpl, 9(11), S52-7. ()
    17. Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD, Harken AH (2003). Diagnostic implications of C-reactive protein. [Review]. Arch Surg, 138(2), 220-4. ()
    18. Raeburn CD, Zimmerman MA, Arya J, Banerjee A, Harken AH (2002). Stem cells and myocardial repair. [Review]. J Am Coll Surg, 195(5), 686-93. ()
    19. Raeburn CD, Zimmerman MA, Arya J, Barsness K, Harken AH (2003). Ischemic preconditioning: fact or fantasy? [Review]. J Card Surg, 17(6), 536-42. ()
    20. Albright TN, Zimmerman MA, Selzman CH (2002). Vasopressin in the cardiac surgery intensive care unit. [Review]. Am J Crit Care, 11(4), 326-30; quiz 331-2. ()
    21. Zimmerman MA, Albright TN, Raeburn CD, Selzman CH (2002). Vasopressin in cardiovascular patients: therapeutic implications. [Review]. Expert Opin Pharmacother, 3(5), 505-12. ()
    22. Raeburn CD, Calkins CM, Zimmerman MA, Arya J, Barsness KA, Harken AH (2002). Toll-like receptors and surgical disease. [Review]. Surgery, 131(5), 477-83. ()
    23. Raeburn CD, Cleveland JC Jr, Zimmerman MA, Harken AH (2001). Organ preconditioning. [Review]. Arch Surg, 136(11), 1263-6. ()
    24. Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM, Barsness K, Harken AH (2002). Clinical applications of cardiovascular angiogenesis. [Review]. J Card Surg, 16(6), 490-7. ()
    25. Selzman CH, Miller SA, Zimmerman MA, Harken AH (2001). The case for beta-adrenergic blockade as prophylaxis against perioperative cardiovascular morbidity and mortality. [Review]. Arch Surg, 136(3), 286-90. ()
    26. Zimmerman MA, Selzman CH, Harken AH (1999). Surgical implications of therapeutic angiogenesis. [Review]. Surgery, 125(3), 243-9. ()

    Book Chapter

    1. Zimmerman MA, Onaca N, Klintmalm GB (2014). Novel immunosuppression of patients with hepatic malignancies. In Transplantation of the Liver (3rd Edition).
    2. Zimmerman MA, Kam I (2014). Choledochoduodenostomy. In Mulholland M, Albo D, Englesbe M, Hawn M, Highes S, Savel M (Eds.), Operative Techniques in Transplant Surgery (1st edition).
    3. Zimmerman MA, Campsen J (2010). Budd-Chiari Syndrome. In Current Surgical Therapy (10th Edition, pp. 329-33).
    4. Campsen J, Zimmerman MA, Bak T (2009). Liver transplantation. In Abernathy’s Surgical Secrets (6th Edition, pp. 433-5).
    5. Campsen J, Zimmerman MA, Bak TE (2009). Kidney and pancreas transplantation. In Abernathy’s Surgical Secrets (6th Edition, pp. 436-8).
    6. Zimmerman MA, Cameron AM, Ghobrial RM (2008). Hepatocellular carcinoma. In Controversies in Liver Transplantation.

    Case Report

    1. Voulgarelis S, Hong JC, Zimmerman MA, Kim J, Scott JP (2020). A novel escalation from veno-venous bypass to veno-venous ECMO during orthotopic liver transplantation. A case report. Perfusion, 36(8), 861-863. ()
    2. Durazo FA, Nicholas AA, Mahaffey JJ, Sova S, Evans JJ, Trivella JP, Loy V, Kim J, Zimmerman MA, Hong JC (2021). Post-Covid-19 Cholangiopathy-A New Indication for Liver Transplantation: A Case Report. Transplant Proc, 53(4), 1132-1137. ()
    3. Kim J, Fons RA, Scott JP, Eriksen CM, Lerret SM, Browning MB, Telega GW, Vitola BE, Hoffman GM, North PE, Vo NN, Zimmerman MA, Hong JC (2018). Transabdominal Intrapericardial Approach in Liver Transplantation for Unresectable Primary Hepatic Functioning Paraganglioma With Invasion Into Hepatic Veins and Suprahepatic Vena Cava: A Surgical and Anesthesia Management Challenge. Transplant Proc, 50(9), 2630-2635. ()
    4. Boettcher BT, Woehlck HJ, Reck SE, Hong JC, Zimmerman MA, Kim J, Zundel MT, Freed JK, Pagel PS (2016). Treatment of Vasoplegic Syndrome With Intravenous Hydroxocobalamin During Liver Transplantation. J Cardiothorac Vasc Anesth, 31(4), 1381-1384. ()
    5. Hong JC, Kim J, Browning M, Wagner A, Lerret S, Segura AD, Zimmerman MA (2017). Modified Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Hepatoblastoma in a Small Infant: How Far Can We Push the Envelope? Ann Surg, 266(2), e16-e17. ()
    6. Woehlck HJ, Boettcher BT, Lauer KK, Cronin DC, Hong JC, Zimmerman MA, Kim J, Selim M (2016). Hydroxocobalamin for Vasoplegic Syndrome in Liver Transplantation: Restoration of Blood Pressure Without Vasospasm. A A Case Rep, 7(12), 247-250. ()
    7. Cheng SS, Berman GW, Merritt GR, Hendrickse A, Fiegel MJ, Teitelbaum I, Campsen J, Wachs M, Zimmerman M, Mandell MS (2011). The response to methylene blue in patients with severe hypotension during liver transplantation. J Clin Anesth, 24(4), 324-8. ()
    8. Campsen J, Zimmerman M, Shoen J, Wachs M, Bak T, Mandell MS, Kam I (2008). Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg, 18(12), 1625-7. ()
    9. Cameron AM, Truty J, Truell J, Lassman C, Zimmerman MA, Kelly BS Jr, Farmer DG, Hiatt JR, Ghobrial R, Busuttil RW (2005). Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy. Transplantation, 80(7), 993-6. ()
    10. Barbick B, Cothren CC, Zimmerman MA, Moore EE (2004). Posttraumatic pneumatocele. J Am Coll Surg, 200(2), 306-7. ()
    11. Selzman CH, Zimmerman MA, Campbell DN (2003). ALCAPA in an adult with preserved left ventricular function. J Card Surg, 18(1), 25-8. ()

    Editorial

    1. Mandell MS, Zimmerman M, Campsen J, Kam I (2008). Bariatric surgery in liver transplant patients: weighing the evidence. Obes Surg, 18(12), 1515-6. ()
    2. Mandell MS, Lindenfeld J, Tsou MY, Zimmerman M (2008). Cardiac evaluation of liver transplant candidates. World J Gastroenterol, 14(22), 3445-51. ()

    Abstract

    1. DiNorcia J, Florman SS, Haydel B, Ruiz RM, Klintmalm G, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial MR, Nydam T, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Khuet ML, Jones CM, Fishbein TM, Busuttil RW, Agopian VG (2018). Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome after Liver Transplantation for Hepatocellular Carcinoma: An Analysis from the US Multicenter HCC Transplant Consortium. Presented at the Pacific Coast Surgical Association 89th Annual Meeting, Napa, CA [Abstract].
    2. Kim J, Martin A, Zimmerman MA, Hong JC (2016). The effect of type and duration of hepatic ischemia on hepatocyte membrane bile transporter expression. Presented at the International Liver Transplant Society Congress, Seoul, Korea [Abstract].
    3. 31Kim J, North PE, Lerret SM, Bernadette VE, Telega GW, Zimmerman MA, Hong JC (2016). Liver transplantation for non-resectable malignant hepatic paraganglioma: the first case report. Presented at the International Liver Transplant Society Congress, Seoul, Korea [Abstract].
    4. Lin S, Ruller C, Gralla J, Kam I, Biggins SW, Zimmerman M, Lewis V, Nydam T (2015). Improved renal function post-liver transplant with earlier everolimus (EVL) conversion. Presented at the American Transplant Congress [Abstract].
    5. Selim M, Johnson C, Saad E, Zimmerman M (2015). Optimal donor/recipient pairing for high KDPI grafts can yield similar survival to medium KDPI grafts. Presented at the American Society of Transplant Surgeons (ASTS) Winter Symposium [Abstract].
    6. Grenz A, Tak E, Kaplan M, Kam I, Eltzschig HK, Zimmerman MA (2014). Induction of CD39 and CD73 during human liver transplantation correlates to ischemic liver injury in knockout mice. Presented at the American Society of Transplant Surgeons (ASTS) Winter Symposium [Abstract].
    7. Zimmerman MA, Grenz A, Tak E, Kaplan M, Kam I, Eltzschig HK (2013). Targeted inhibition of equilibrative nucleoside transporters protects during murine hepatic ischemia/reperfusion injury. Presented at the American Society of Transplant Surgeons (ASTS) Winter Symposium [Abstract].
    8. Shaked A, Feng S, Punch J, Reyes J, Levitsky J, Klintmalm G, Zimmerman M, DesMarais M, Kopeskie H, Priore A, Bridges N, Sayre P (2012). Initial Outcomes of ITN030ST: Early Post-liver Transplant Immunosuppression Withdrawal. Presented at the American Transplant Congress [Abstract]. 12(Suppl 3), 197.
    9. Campsen J, Zimmerman MA, Trotter J, Hong JC, Freise C, Brown R, Cameron AM, Ghobrial RM, Kam I, Busuttil RW, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm G (2012). HBV reinfection after liver transplant is associated with increased recurrent hepatocellular carcinoma and worse survival. Presented at the American Transplant Congress [Abstract]. 12(Suppl 3), 199.
    10. Campsen J, Zimmerman MA, Trotter J, Hong JC, Freise C, Brown R, Cameron AM, Ghobrial RM, Kam I, Busuttil RW, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm G (2012). Multicenter review of liver transplant for hepatitis B related liver disease: Females and black American do worse. Presented at the American Transplant Congress [Abstract]. 12(Suppl 3), 84.
    11. Zimmerman MA, Grenz A, Tak E, Kaplan M, Eltzschig H (2012). Hepatocyte-specific protection by A2B adenosine receptors during ischemia-reperfusion injury of the liver. Presented at the American Society of Transplant Surgeons (ASTS) Winter Symposium [Abstract].
    12. Zimmerman MA, Baker T, Freise C, Hong JC, Kumer S, Abt P, Cotterell A, Goodrich NP, Merion RM (2012). Aggregate morbidity and resolution of biliary complications after living donor and deceased donor liver transplantation: A report from the adult-to- adult living donor liver transplantation cohort study (A2ALL). Presented at the American Transplant Congress [Abstract]. 12(Suppl 3), 108.
    13. Zimmerman MA, Kaplan M, Grenz A, Eltzschig H (2011). Adenosine 2B receptor signaling in muring hepatic ischemia-reperfusion injury. Presented at the American Surgical Congress [Abstract].
    14. Kelly, MA, Kaplan M, Smith M, Wachs M, Bak T, Kam, I, Zimmerman MA (2011). Sirolimus reduces the risk of significant hepatic fibrosis and after liver transplantation for hepatitis C virus (HCV): a single center experience. Presented at the American College of Surgeons [Abstract].
    15. Kaplan M, Kelly M, Wachs M, Bak T, Nydam T, Kam I, Zimmerman MA (2010). Sirolimus- based immunosuppression has no influence on recurrent primary sclerosing cholangitis following orthotopic liver transplantation. Presented at the The Liver Meeting [Abstract].
    16. Zimmerman MA, Flores SC (2009). Autoimmune-mediated vascular injury in the setting of type I diabetes. Presented at the American Surigical Congress [Abstract]. 151, 266.
    17. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kaplan M, Kam I (2008). Recurrent primary biliary cirrhosis after liver transplantation at a center practicing corticosteroid minimization. Presented at the American Transplant Congress [Abstract]. 8(supplement 2), 286.
    18. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Kam I (2008). Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Presented at the American Transplant Congress [Abstract]. 8(supplement 2), 470.
    19. Jani A, Lu L, Zimmerman MA, Ljubanovic D, Edelstein C (2008). Caspase-3 activation in a porcine kidney model of extended criteria donation. Presented at the American Transplant Congress [Abstract]. 8(supplement 2), 428.
    20. Zimmerman MA, Ghobrial RM, Cameron AM, Tong MJ, Busuttil RW (2006). Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Presented at the American Transplant Congress [Abstract]. 830(supplement).
    21. Zimmerman, MA, Ghobrial RM, Klintmalm GB, Trotter JF, Cameron AM, Gornbein J, Farmer DG, Yersiz H, Busuttil RW (2006). A short-term predictive model of survival following liver re-transplantation. Presented at the Liver Meeting [Abstract].
    22. Gordon SA, Uchiyama K, McDiarmid SV, Datta S, Lipshutz G, Cameron AM, Carmdoy IC, Kelly B, Ruiz R, Zimmerman MA, Yersiz H, Farmer DG, Ghobrial RM, Busuttil RW (2005). The effect of immunosuppression on ABO incompatible liver transplantation outcomes in the modern era [Abstract]. 11, C36.
    23. Zimmerman MA, Selzman CH, Dinarello C, Raeburn CD, Sorensen BS, Harken AH (2002). Intimal hyperplasia requires adhesion molecule expression but not interleukin-1b. Presented at the American College of Surgeons [Abstract]. 195, S98.
    24. Raeburn CD, Dinarello CA, Zimmerman MA, Calkins CM, Meng X, Harken AH (2001). Neutralization of IL-18 protects cardiac function during endotoxemia with minimal effect on TNF [Abstract]. 100, 245.
    25. Zimmerman MA, Selzman CH, Raeburn CD, Hamiel C, Harken AH (2001). Interleukin-11 attenuates human vascular smooth muscle cell proliferation [Abstract]. 100, 268.
    26. Zimmerman MA, Selzman CH, Reznikov LL, Miller SA, Raeburn CD, Emmick J, Meng X, Harken AH (2001). TNFa is required for neointimal hyperplasia following mouse carotid injury. Presented at the American College of Surgeons [Abstract]. 25.
    27. Zimmerman MA, Selzman CH, Miller SA, Raeburn CD, Harken AH (2001). TNFa is required for post-injury neointimal hyperplasia [Abstract]. (Supp II), 180.
    28. Miller SA, Selzman CH, Pulido EJ, Zimmerman MA, Whitehill TA, Harken AH (2000). Interleukin-10 (IL-10) attenuates the arterial inflammatory response to injury. Presented at the American College of Surgeons [Abstract]. 191, S72.

    Video/Film/CD/Web/Podcast

    1. Zimmerman M, Tak E, Kaplan M, Mandell MS, Eltzschig HK, Grenz A (2012). Use of a hanging-weight system for liver ischemia in mice. [J Vis Exp]. United States. ()

  • News & Podcasts

    News

  • Clinical Trials